PLRX
Pliant Therapeutics Inc.
$1.68
$0.00(0.00%)
46
Overall
60
Value
50
Tech
28
Quality
Market Cap
$87.79M
Volume
245.38K
52W Range
$1.10 - $16.10
Target Price
$2.96
Order:
Income Statement
| Metric | Trend | Chart | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|
| REVENUE | |||||||
| Total Revenue | $41.8M | $7.6M | $9.7M | $1.6M | -- | ||
| Total Revenue | $41.8M | $7.6M | $9.7M | $1.6M | -- | ||
| GROSS PROFIT | |||||||
| Gross Profit | $41.8M | $7.6M | $9.7M | $1.6M | -- | ||
| OPERATING EXPENSES | |||||||
| Operating Expenses | $83.5M | $105.1M | $136.9M | $185.7M | $228.4M | ||
| Research & Development | $66.2M | $77.5M | $96.9M | $127.8M | $169.3M | ||
| Research Expense | $66.2M | $77.5M | $96.9M | $127.8M | $169.3M | ||
| Selling, General & Administrative | $17.3M | $27.6M | $39.9M | $57.9M | $59.1M | ||
| General & Administrative Expenses | $17.3M | $27.6M | $39.9M | $57.9M | $59.1M | ||
| Salaries & Wages | -- | -- | -- | $44.5M | $37.6M | ||
| Depreciation & Amortization | $1.3M | $1.5M | $1.8M | $1.8M | $2.1M | ||
| Depreciation & Amortization | $1.3M | $1.5M | $1.8M | $1.8M | $2.1M | ||
| Other Operating Expenses | $-513.0K | $-1.1M | $-1.5M | $-2.5M | $-2.5M | ||
| OPERATING INCOME | |||||||
| Operating income | $-41.6M | $-97.5M | $-127.2M | $-184.1M | $-228.4M | ||
| EBITDA | $-40.3M | $-95.7M | $-120.7M | $-162.1M | $-202.2M | ||
| NON-OPERATING ITEMS | |||||||
| Interest Expense (Non-Operating) | -- | -- | $791.0K | $1.3M | -- | ||
| Intinc | $478.0K | -- | -- | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $478.0K | -- | $-3.9M | $-22.8M | -- | ||
| Other Income/Expense | $-15.0K | $-1.0K | -- | -- | -- | ||
| Other Special Charges | $-366.0K | -- | -- | -- | -- | ||
| PRE-TAX INCOME | |||||||
| EBIT | $-41.6M | $-97.3M | $-122.5M | $-161.3M | $-210.3M | ||
| Pre-Tax Income | $-41.6M | $-97.5M | $-123.3M | $-184.1M | $-210.3M | ||
| NET INCOME | |||||||
| Net Income | $-41.5M | $-97.3M | $-123.3M | $-161.3M | $-210.3M | ||
| Net Income (Continuing Operations) | $-41.5M | $-97.3M | $-123.3M | $-161.3M | $-210.3M | ||
| Net Income (Discontinued Operations) | $-41.5M | $-97.3M | $-123.3M | $-161.3M | $-210.3M | ||
| Net Income (Common Stockholders) | $-41.5M | $-97.3M | $-123.3M | $-161.3M | $-210.3M | ||
| Normalized Income | -- | -- | -- | -- | $-226.1M | ||
| TOTALS | |||||||
| Total Expenses | $83.5M | $105.1M | $136.9M | $185.7M | $228.4M | ||
| SHARE & EPS DATA | |||||||
| Average Shares Outstanding | $21.3M | $35.8M | $42.0M | $58.7M | $60.5M | ||
| Average Shares Outstanding (Diluted) | $21.3M | $35.8M | $42.0M | $58.7M | $60.5M | ||
| Shares Outstanding | $35.7M | $36.1M | $58.9M | $60.2M | $61.2M | ||
| Basic EPS | $-1.95 | $-2.71 | $-2.94 | $-2.75 | $-3.47 | ||
| Basic EPS (Continuing Operations) | $-1.95 | $-2.71 | $-2.94 | $-2.75 | $-3.47 | ||
| Diluted EPS | $-1.95 | $-2.71 | $-2.94 | $-2.75 | $-3.47 | ||
| Diluted EPS (Continuing Operations) | $-1.95 | $-2.71 | $-2.94 | $-2.75 | $-3.47 | ||
| OTHER METRICS | |||||||
| Net Income From Other Gains Losses | $112.0K | $272.0K | $4.7M | -- | -- | ||
| Other Gand A | $17.3M | $27.6M | $39.9M | $57.9M | $59.1M | ||
| Rent And Landing Fees | $2.5M | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PLRX | $1.68 | 0% | 245.38K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Pliant Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW